In this time of great concern and confusion surrounding the novel coronavirus, SARS-CoV-2, you can rest assured that we are taking action to safeguard the health and wellbeing of our employees and the patients in your clinical trials. We are also committed to keeping you informed as we navigate this changing landscape.
On March 19, 2020, Pennsylvania Gov. Tom Wolf ordered closure of all non-life sustaining businesses effective March 21, 2020, at 12:01 a.m.
We want to assure you that Myoderm will continue to operate and ensure that your sites have the drugs and ancillary supplies they need for the patients in your trials.
Although we are headquartered and have operations in Pennsylvania, as a critical part of the pharmaceutical development supply chain, we have determined that Myoderm falls into the life-sustaining category and will continue operations as planned.
Life-sustaining businesses include:
- Scientific research and development services
- Pharmaceutical and medical manufacturing
- Medical equipment and supplies manufacturing
- Medical and diagnostic laboratories
We remain in close contact with Life Sciences Pennsylvania, which is working with Pennsylvania officials to ensure that we can continue to provide you and your sites with the medications and supplies you need to continue your critical life-sustaining research.
We will be in immediate contact with you should we receive any information that impacts your trials. We appreciate the trust you place in us and want you to feel confident that we continue to earn it.
If you have specific concerns about supplies for your trial, your Myoderm representative will be happy to answer your questions.